Glaucoma

Skye Bioscience to Present at Jefferies Global Healthcare Conference

Retrieved on: 
måndag, juni 3, 2024
Glaucoma, Obesity, SAN, Conference

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair, Punit Dhillon, will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference being held in New York City from June 5th to 6th.

Key Points: 
  • SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair, Punit Dhillon, will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference being held in New York City from June 5th to 6th.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.

Retrieved on: 
onsdag, maj 29, 2024
Medical Devices, Health, General Health, Pharmaceutical, Optical, Biotechnology, Patient, Cataract, Drainage, FDA, Innovation system, CPT, Glaucoma, MBA, MD, Ophthalmology, Pharma, Cosmetics

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

Key Points: 
  • Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
  • LACRIFILL Canalicular Gel allows patient’s eyes to be bathed in their own natural tears.
  • “It’s been so exciting to be part of the launch of LACRIFILL Canalicular Gel, an interventional dry eye treatment that helps ophthalmologists with cataract, glaucoma and refractive surgeries and all of their dry eye needs.
  • Nordic Pharma is attending Kiawah Eye 2024 in Kiawah Island, SC from May 30-June 1 to share information about LACRIFILL Canalicular Gel and take orders.

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

Retrieved on: 
tisdag, maj 28, 2024
Patient, Month, Ophthalmology, IOP, Regression analysis, FDA, Disease, Glaucoma, Intraocular pressure, MD, Medicine, MIGS, Institutional review board, Field line, OMNI, Entrepreneurship, Pharmaceutical industry

This new analysis evaluated the association between the severity of glaucoma and the intraocular pressure ("IOP") and medication outcomes for patients treated with the OMNI Surgical System ("OMNI").

Key Points: 
  • This new analysis evaluated the association between the severity of glaucoma and the intraocular pressure ("IOP") and medication outcomes for patients treated with the OMNI Surgical System ("OMNI").
  • The findings suggest that ab interno canaloplasty coupled with trabeculotomy using OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients.
  • This data challenges the belief that advanced disease stage is a barrier to successful treatment outcomes for minimally invasive glaucoma surgery ("MIGS").
  • Jamie E. Dickerson, Alison E. Harvey, Reay H. Brown, Ab Interno Canaloplasty and Trabeculotomy Outcomes for Mild, Moderate, and Advanced Open-Angle Glaucoma: A ROMEO Analysis, Clinical Ophthalmology, 2024:18

Glaukos Announces Participation in Upcoming Investor Conferences

Retrieved on: 
tisdag, maj 28, 2024
Biotechnology, Pharmaceutical, Optical, Surgery, General Health, Health, Medical Devices, Health Technology, Corporation, Conference, Glaucoma, Retina, GKOS

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:
    William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024, at 1:40 p.m.
  • ET in Chicago, IL
    Truist MedTech Conference on Tuesday, June 18, 2024, at 12:45 p.m.
  • ET in Boston, MA
    A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com .

Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®

Retrieved on: 
tisdag, maj 28, 2024
Research, General Health, Pharmaceutical, Optical, Specialty, Retail, Clinical Trials, Science, Surgery, Medical Supplies, FDA, Health, The Bell Tower, Trial of the century, Viral, Bausch, Allergy, OD, Inflammation, Steroid, Fungal infection, Action, OnDemand, AOA, Telecanthus, CDT, Glaucoma, Sclera, Infection, Intraocular pressure, Contact, American Optometric Association, Conjunctiva, Cerebral edema, Music City Center, Macular edema, Complex, Eye injury, Thought, System, Employment, Convention, Contact lens, Slit lamp, Vaccinia, Patient, Incidence, Safety, Keratitis, Bausch & Lomb, Herpes simplex, Visual acuity, Taste, Iris, Eyelash, Risk, IOP, Lens (vertebrate anatomy), Astigmatism, Pigment, Efficacy, Verge, Ocular hypertension, Eye, Abstract, Human, Pain, Optic nerve, History, Palm, Chickenpox, EYE

The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.

Key Points: 
  • The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.
  • “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et al.
  • “Improvement in Non-Invasive Tear Break-Up Time after Instillation of One Drop of Brimonidine Tartrate 0.025%.” Moore et al.
  • During the event, attendees will have the opportunity to learn about Bausch + Lomb’s latest innovations, including Bausch + Lomb INFUSE® for Astigmatism and Blink NutriTears.

Iridex Reports First Quarter 2024 Financial Results

Retrieved on: 
tisdag, maj 14, 2024
G6, Glaucoma, Sale, Absorption, IRIX, Retina, Video game

MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update.
  • Fortunately, we are seeing additional firming in the second quarter as well as indications that a good portion of the orders that have been queueing up are expected to ship during the second quarter,” said David Bruce, President and CEO of Iridex.
  • “In the first quarter, solid growth from the sale of Pascal® scanning laser systems and G6 probes internationally was offset by the deferrals and resulting revenue declines of other products.
  • Cash use was $1.6 million in the first quarter of 2024.

iHealthScreen Developed and Validated Risk Prediction Models for Cardiovascular Diseases Using Individual’s Retinal Color Images and Health Data

Retrieved on: 
fredag, maj 24, 2024
Cardiology, Biometrics, Telemedicine, Virtual Medicine, Optical, Health, Artificial Intelligence, Health Technology, Technology, CE, Patient, Diabetic retinopathy, AMD, Chad (slang), Risk, Diagnosis, Glaucoma, Stroke, ESC Congress, Congress, Death, Myocardial infarction, Disability, DR, Physician, Vance DeGeneres, Splenic infarction, IPredict

iPredict™ Stroke and heart attack prediction models provide AI-based automated prediction scores for incident stroke and heart attack (i.e., myocardial infarction (MI)) which identifies the individuals who are at risk of having stroke and MI within 5 years.

Key Points: 
  • iPredict™ Stroke and heart attack prediction models provide AI-based automated prediction scores for incident stroke and heart attack (i.e., myocardial infarction (MI)) which identifies the individuals who are at risk of having stroke and MI within 5 years.
  • The iPredict stroke and MI prediction models aim to help prevent strokes and heart attacks, saving millions of people from deaths or disabilities.
  • Using the high-resolution retinal color images of the individual’s eyes and health data, the iPredict™ AI System’s stroke and MI prediction results will be available in fully automated reports in less than 60 seconds.
  • iHealthScreen company is open to partnerships for collaboration and/or co-development of its products in various territories.

Upneeq® Wins 2024 Shape Skin Award, “Best for Lift”, in the Professional Treatment Category

Retrieved on: 
fredag, maj 17, 2024
Cosmetics, Men, Alternative Medicine, Retail, Health, Consumer, Pharmaceutical, Optical, Bridal, General Health, LGBTQ+, Fitness & Nutrition, Women, Seniors, Blood pressure, Patient, Telecanthus, Headache, Xanthine oxidase inhibitor, Pressure, Myasthenia gravis, Mouth, Eye injury, Blepharoplasty, Risk, Heart, FDA, Shape (magazine), Digital, Glaucoma, Stroke, Safety, Prostate, RVL, Dermatology, MD, Hypertension, Human, Eye, Aneurysm, Brain, Horner's syndrome, Beauty, Skin, Multimedia, Pharmaceutical industry

RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named “Best for Lift” in the professional category.

Key Points: 
  • RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named “Best for Lift” in the professional category.
  • The product was also named as a "Best Professional Grade'' treatment by editors in 2022 and received a 2023 Shape Beauty Award for “Best In-Office" treatments.
  • 37 winners were ultimately chosen, and judges awarded Upneeq for its subtle but noticeable lift for droopy eyelids.
  • “Shape is an empowering and trusted voice in health and beauty with a committed community to quality self-care.

North America Legal Cannabis Market Report 2024-2032: Hemp-Derived CBD Expanding Opportunities, Marijuana Oils and Tinctures Addressing Health Issues, Rising Recreational Use - ResearchAndMarkets.com

Retrieved on: 
fredag, maj 17, 2024
Cannabis, Natural Resources, Taste, COVID-19, Risk, Conditional sentence, Alzheimer's disease, Seizure, Depression, THC, Anxiety, Migraine, Glaucoma, Asthma, Market, Growth, Appetite, Cannabidiol, Seed, Chronic pain, Inflammation, Flower, Vomiting, Country, Hearing, Drug

The "North America Legal Cannabis Market Report by Products Derived, Distribution Channel, and Country 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Legal Cannabis Market Report by Products Derived, Distribution Channel, and Country 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The report has also provided a comprehensive analysis of the competitive landscape in the North America legal cannabis market.
  • The report has provided a detailed breakup and analysis of the North America legal cannabis market based on the products derived.
  • What is the breakup of the North America legal cannabis market based on the distribution channel?

Canadian seniors at risk of vision loss due to financial barriers, according to Specsavers survey

Retrieved on: 
tisdag, maj 14, 2024
Insurance, Specsavers, Prescription, AMD, Optometry, Risk, OCT, Optical coherence tomography, Glaucoma, Health, Leger, Incidence, Vance DeGeneres, Eye, Quality of life, Paratriathlon

Optometrists are equipped to detect the earliest signs of eye diseases," says Naomi Barber, Clinical Services Director at Specsavers.

Key Points: 
  • Optometrists are equipped to detect the earliest signs of eye diseases," says Naomi Barber, Clinical Services Director at Specsavers.
  • When examining the factors putting seniors' vision at risk, half do not have vision health benefits and one-in-four have skipped or delayed updating their eyewear prescriptions due to financial barriers.
  • Regular eye exams are important as 75 per cent of vision loss is preventable and treatable.1
    "We believe that Canadian seniors deserve better.
  • 1 A Report Card on Vision Health in Canada, The Canadian Council of the Blind and Fighting Blindness Canada.